Myeloproliferative Neoplasms

Nicolaus Kröger; Yves Chalandon

doi:10.1007/978-3-030-02278-5_76

Myeloproliferative Neoplasms

Review

In: The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 76.

Authors

Nicolaus Kröger¹, Yves Chalandon²

Book Editors

Enric Carreras¹, Carlo Dufour², Mohamad Mohty³, Nicolaus Kröger⁴

Affiliations

¹ Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
² Department of Oncology, Hematology Division, Hôpitaux Universitaires de Genève, University of Geneva, Geneva, Switzerland

Book Affiliations

¹ Spanish Bone Marrow Donor Registry, Josep Carreras Foundation and Leukemia Research Institute, Catalunya, Barcelona, Spain
² Hematology Unit, IRCCS Giannina Gaslini, Geneva, Switzerland
³ Department of Hematology, Pierre and Marie Curie University, Paris, France
⁴ Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppend, Hamburg, Germany

Excerpt

Polycythemia vera (PV) and essential thrombocythemia (ET) have a favorable outcome without need for allo-HSCT unless the disease progressed to post-ET/PV myelofibrosis or secondary AML (Lussana et al. 2014).

Sections

Publication types

Review